Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Checkpoint inhibitors, Enhertu in spotlight as ASCO resumes in-person meetings

CSL Vifor plans UK launch after NICE backs rare disease drug Tavneos

Astellas files menopause drug fezolinetant in US, setting up Feb verdict

Frontiers Health Steering Committee spotlight: Megan Coder

Endo files for bankruptcy as it agrees opioid settlement

Xencor

Janssen J&J Johnson and Johnson pharmaceutical companies

News/ News/ Oncology

J&J bulks up in bispecifics with $1.3bn Xencor alliance

Phil Taylor bispecific antibody, blood cancer, immuno-oncology, Janssen, Johnson & Johnson, Oncology, partnering, Xencor 0 Comment

Fresh from claiming its first bispecific antibody approval, Johnson & Johnson has delved deeper into the category with

X

J&J bulks up in bispecifics with $1.3bn Xencor alliance

https://pharmaphorum.com/news/jj-bulks-up-in-bispecifics-with-1-3bn-xencor-alliance/

Novartis-AU-HQ

Novartis buys into bispecific antibodies with Xencor deal

Richard Staines bispecific antibody, cancer, immuno-oncology, Novartis, Xencor 0 Comment

Agreement could add to Novartis’ immuno-oncology pipeline.

X

Novartis buys into bispecific antibodies with Xencor deal

https://pharmaphorum.com/news/novartis-signs-150m-antibody-deal-xencor/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

End of the line for Sanofi's SERD amcenestrant as it fails first-line trial
GSK gets June 2023 FDA decision date for momelotinib
Merck makes circular RNA play with $3.5bn Orna alliance
On heels of new data, Gilead pays $455m for Asian Trodelvy rights
Roche eyes April FDA verdict on Polivy as first-line lymphoma therapy

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com